InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

Current share price for NEU : $18.000 0.52 (2.97%)+

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,282 Neuren highlights participation in PMSF Family Conference 24 Jul 2026 9:57AM $16.460 $18.000 risen by 9.36%
$2,282 DAYBU recommended for approval in the European Union 29 Jun 2026 7:43AM $12.200 $18.000 risen by 47.54%
$2,282 Application for quotation of securities - NEU 18 Jun 2026 4:49PM $13.250 $18.000 risen by 35.85%
$2,282 Notification of cessation of securities - NEU 1 Jun 2026 5:47PM $14.210 $18.000 risen by 26.67%
$2,282 Notification regarding unquoted securities - NEU 1 Jun 2026 5:40PM $14.210 $18.000 risen by 26.67%
$2,282 Results of Meeting 27 May 2026 4:00PM $13.810 $18.000 risen by 30.34%
$2,282 AGM Chair Address & CEO Presentation 27 May 2026 1:22PM $14.410 $18.000 risen by 24.91%
$2,282 Update - Notification of buy-back - NEU 14 May 2026 7:30AM $12.710 $18.000 risen by 41.62%
$2,282 Launch of Investor Hub to enhance shareholder engagement 12 May 2026 3:56PM $12.870 $18.000 risen by 39.86%
$2,282 Notification of cessation of securities - NEU 12 May 2026 8:34AM $13.390 $18.000 risen by 34.43%
$2,282 Update - Notification of buy-back - NEU 12 May 2026 8:32AM $13.390 $18.000 risen by 34.43%
$2,282 Update - Notification of buy-back - NEU 11 May 2026 8:45AM $12.800 $18.000 risen by 40.63%
$2,282 Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025 7 May 2026 9:53AM $12.320 $18.000 risen by 46.10%
$2,282 Update - Notification of buy-back - NEU 6 May 2026 10:31AM $12.510 $18.000 risen by 43.88%
$2,282 Update - Notification of buy-back - NEU 29 Apr 2026 8:45AM $11.930 $18.000 risen by 50.88%
$2,282 Virtual AGM online guide 24 Apr 2026 1:27PM $12.225 $18.000 risen by 47.24%
$2,282 Notice of Annual General Meeting/Proxy Form 24 Apr 2026 1:22PM $12.225 $18.000 risen by 47.24%
$2,282 Appendix 4G 24 Apr 2026 1:05PM $12.260 $18.000 risen by 46.82%
$2,282 2025 Annual Report to shareholders 24 Apr 2026 12:58PM $12.140 $18.000 risen by 48.27%
$2,282 Update - Notification of buy-back - NEU 21 Apr 2026 8:56AM $12.480 $18.000 risen by 44.23%
$2,282 Update - Notification of buy-back - NEU 20 Apr 2026 8:32AM $12.490 $18.000 risen by 44.12%
$2,282 Update - Notification of buy-back - NEU 17 Apr 2026 8:48AM $12.480 $18.000 risen by 44.23%
$2,282 Notification of cessation of securities - NEU 10 Apr 2026 4:55PM $12.520 $18.000 risen by 43.77%
$2,282 DAYBUE STIX now broadly available in US for Rett syndrome 8 Apr 2026 9:47AM $12.300 $18.000 risen by 46.34%
$2,282 Notification of cessation of securities - NEU 26 Mar 2026 5:49PM $11.850 $18.000 risen by 51.90%

1 - 25 of 822 results

Page 1 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.